Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

21.1%

8 terminated out of 38 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

8%

3 trials in Phase 3/4

Results Transparency

44%

7 of 16 completed with results

Key Signals

7 with results67% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (13)
Early P 1 (1)
P 1 (6)
P 2 (5)
P 3 (1)
P 4 (2)

Trial Status

Completed16
Terminated8
Unknown6
Withdrawn4
Not Yet Recruiting1
Enrolling By Invitation1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (38)

Showing 20 of 20 trials
NCT05150002Not ApplicableTerminatedPrimary

Cervical Spinal Cord Stimulation in Patients With Cerebral Vasospasm After Subarachnoid Haemorrhage: VasoStim Study

NCT05230134Not ApplicableEnrolling By Invitation

Cervical Sympathetic Block in Patients With Cerebral Vasospasm

NCT06303349Not ApplicableCompletedPrimary

Predictive Model for the Occurrence of Cerebral Vasospasm Complicating Subarachnoid Haemorrhage by Combined Analysis of the Kinetics of a Panel of Biomarkers.

NCT01996436Phase 4TerminatedPrimary

The Intra-arterial Vasospasm Trial

NCT00585559Phase 3Terminated

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

NCT06560372Not ApplicableRecruiting

Incidence, Characteristics and Evolution of Cerebral Vasospasm With Clinical Impact in Moderate to Severe Traumatic Brain Injury Complicated by Subarachnoid Hemorrhage at Martinique University Hospital

NCT06893588Not Yet RecruitingPrimary

Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

NCT02056769Not ApplicableActive Not Recruiting

CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage

NCT02389634CompletedPrimary

Identification of Novel Molecular Markers for Vasospasm

NCT04691271Not ApplicableUnknown

Stellate Ganglion Block and Cerebral Vasospasm

NCT04208477Not ApplicableCompleted

"The Effect of Stellate Ganglion Block in Severe Brain Injury"

NCT00871065Phase 2WithdrawnPrimary

Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm

NCT03611790Not ApplicableCompletedPrimary

Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)

NCT04613960Phase 2Unknown

Magnesium Treating Subarachnoid Hemorrhage Vasospasm

NCT01595802CompletedPrimary

Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm

NCT03517670CompletedPrimary

Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm

NCT03214705Completed

Role of CT Perfusion in Predicting Poor Outcome After Subarachnoid Hemorrhage

NCT03028298Phase 1Unknown

Sildenafil for DCI

NCT04512859Not ApplicableUnknown

Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage

NCT02712788Phase 2TerminatedPrimary

Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Scroll to load more

Research Network

Activity Timeline